Halting progressive multifocal leukoencephalopathy with pembrolizumab: the case of a patient with multiple sclerosis under fingolimod

J Neurol. 2024 Feb;271(2):729-732. doi: 10.1007/s00415-023-12055-9. Epub 2023 Nov 1.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Fingolimod Hydrochloride / adverse effects
  • Humans
  • JC Virus*
  • Leukoencephalopathy, Progressive Multifocal* / chemically induced
  • Leukoencephalopathy, Progressive Multifocal* / diagnostic imaging
  • Leukoencephalopathy, Progressive Multifocal* / drug therapy
  • Multiple Sclerosis* / complications
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting* / complications
  • Multiple Sclerosis, Relapsing-Remitting* / drug therapy
  • Natalizumab / adverse effects

Substances

  • Fingolimod Hydrochloride
  • pembrolizumab
  • Antibodies, Monoclonal, Humanized
  • Natalizumab